Neuroimaging characteristics in subgroup of GBMs with p53 overexpression

Journal of Neuroimaging

Volumn 17, Issue 2, 2007, Pages 168-174

  Mut, Melike ^a,b   Turba, Ulku C ^c   Botella, Anali Conesa ^a   Baskurt, Erol ^c   Lopes, M Beatriz S ^a   Shaffrey, Mark E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b YEDITEPE UNIVERSITY   (Turkey)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Glioblastoma; Magnetic resonance imaging; p53

Indexed keywords

CONTRAST MEDIUM; PROTEIN P53;

ADULT; ARTICLE; BRAIN EDEMA; BRAIN TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ENHANCEMENT; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PREOPERATIVE EVALUATION; PROTEIN EXPRESSION; TUMOR NECROSIS; TUMOR VOLUME;

ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247278764     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2007.00112.x     Document Type: Article

References (26)

1. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-6899.
2. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-223.
3. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1999;1:44-51.
4. Bogler O, Huang HJ, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors. Glia 1995;15:308-327.
5. Milner J. Structures and functions of the tumor suppressor p53. Pathol Biol 1997;45:797-803.
6. Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg 1998;85:1460-1467.
7. Kirsch DG, Kastan MB. Tumor suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998;16:3158-3168.
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
9. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-847.
10. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-530.
11. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 1993;52:31-38.
12. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994;9:949-954.
13. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 1993;3:229-235.
14. Birner P, Piribauer M, Fischer I, et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 2002;9:703-707.
15. Burton EC, Lamborn KR, Forsyth P, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002;8:180-187.
16. Morita M, Rosenblum MK, Bilsky MH, Fraser RA, Rosenfeld MR. Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neuro-Oncol 1996;27:259-266.
17. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992;34:463-469.
18. Tervonen O, Forbes G, Scheithauer BW, Dietz MJ. Diffuse "fibrillary"astrocytomas: correlation of MRI features with histopathologic parameters and tumor grade. Neuroradiology 1992;34:173-178.
19. Dean BL, Dryer BP, Bird CR, Flom RA, Hodak JA, Coons SW, Carey RG. Gliomas: classification with MR imaging. Radiology 1990;174:411-415.
20. Asari S, Makabe T, Katayama S, Itoh T, Tsuchida S, Ohmoto T. Assessment of the pathological grade of astrocytic gliomas using an MRI score. Neuroradiology 1994;36:308-310.
21. Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998;42:1044-1056.
22. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-198.
23. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865-874.
24. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG II. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11:8600-8605.
25. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303-4306.
26. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 2000;26:67-73.